newsfilter
← Latest News
Business Wire·

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

  • Alpha Cognition Inc. appointed Bethany Sensenig to its Board of Directors effective April 15, 2026.
  • Sensenig brings decades of leadership experience in finance, corporate strategy, & operations from prior roles at Radius Health, 9 Meters Biopharma, Minovia Therapeutics, & Biogen Inc.
  • CEO Michael McFadden stated Sensenig's expertise will be instrumental in advancing the commercial launch of ZUNVEYL & the sublingual program.
  • Len Mertz announced he will not seek re-election to the Board of Directors, where he previously served as Chairman, Audit Committee Chair, & Governance Committee member.
  • The Company thanked Mertz for his leadership in advancing Alpha Cognition to public markets & progressing its pipeline to an FDA-approved product.
  • Alpha Cognition is developing ZUNVEYL for Alzheimer's disease & ALPHA-1062 for moderate to severe Alzheimer's dementia & Cognitive Impairment with mTBI.
  • The news release includes forward-looking statements regarding business strategy, capital requirements, clinical activities, & regulatory approvals subject to various risks.